Secondary analysis of 50 AChR antibody-positive generalised MG patients from the phase 3 ADAPT trial (efgartigimod n=40, placebo n=10): efgartigimod lowered AChR-specific IgG and its complement, internalisation and blocking effects; double responders had greater reductions.
Secondary analysisn = 50
Khani-Habibabadi et al. Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod